---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-040701"
form_type: "8-K"
ticker: "LUCD"
cik: "0001799011"
company_name: "Lucid Diagnostics Inc."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:55:56.646910+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Lucid Q3 EsoGuard rev $783K (+392% seq.), net loss $14.2M

## Summary
- EsoGuard test volume 2,575 (17% sequential increase, 137% YoY).
- EsoGuard revenue $783K, up 392% sequentially and 930% YoY; net loss $14.2M ($0.34 per share).
- Non-GAAP adjusted loss $9.3M ($0.22 per share); cash $24.1M vs $32.6M at June 30.
- Clinical utility data: near-perfect concordance from three studies totaling over 1,500 patients.
- EsoGuard 2.0 launched with multiplexed triplicate consensus; NGS platform upgrade underway.

## SEC filing metadata
- accession: 0001493152-23-040701
- form_type: 8-K
- ticker: LUCD
- cik: 0001799011
- company_name: Lucid Diagnostics Inc.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799011/000149315223040701/0001493152-23-040701-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799011/000149315223040701/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-040701
- JSON: https://secwatch.observer/filing/0001493152-23-040701.json
- Plain text: https://secwatch.observer/filing/0001493152-23-040701.txt

## Key facts
- Earnings Releases
  Lucid Diagnostics Inc. reported the three and nine months ended September 30, 2023 results: revenue $0.8 million, net income $14.2 million, or $(0.34) per common share, EPS $(0.34) per common share.
  - Period: the three and nine months ended September 30, 2023
  - Revenue: $0.8 million
  - Net income: $14.2 million, or $(0.34) per common share
  - EPS: $(0.34) per common share
  - Result: reported results
  source text: and platform expected to significantly lower per-sample sequencing costs. Financial Results ● For the three months ended September 30, 2023, EsoGuard related revenues were $0.8 million. Operating expenses were approximately $11.9 million, including stock-based compensation expenses of $1.3 million. GAAP net loss was approximately $14.2 million, or $(0.34) per
  evidence_url: https://www.sec.gov/Archives/edgar/data/1799011/000149315223040701/0001493152-23-040701-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.